Clinical Trials
2 trialsNCT06295809 2026-05-08
INTerpath-007
Merck Sharp & Dohme LLC
Phase 2/3 Terminated
NCT06947928 2026-04-17
Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
TuHURA Biosciences, Inc.
Phase 2/3 Recruiting